Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, 610041, People's Republic of China.
Cancer Immunol Immunother. 2024 Jan 27;73(2):32. doi: 10.1007/s00262-023-03616-y.
The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.
恶性腹水（MA）的出现表明卵巢癌、胃肠道癌、乳腺癌和胰腺癌患者预后不良。白细胞介素-10（IL-10）是一种具有免疫调节作用的多效细胞因子，在肿瘤微环境中发挥作用。MA 中 IL-10 的水平因癌症类型和患者而异，影响癌症的进展和结局。IL-10 源自各种免疫细胞和癌细胞，有助于 MA 中复杂的信号通路。虽然全身给予 IL-10 治疗 MA 的疗效证据有限，但它仍作为一种有前途的治疗策略出现，因为它可以直接增加 CD8+T 细胞的细胞毒性并激活耗竭的 CD8+肿瘤浸润淋巴细胞（TILs）。当与 MA 治疗中的其他免疫疗法联合使用时，IL-10 信号阻断也显示出巨大的潜力。我们综述了 MA 中 IL-10 的水平、来源和功能，并综述了目前针对 IL-10 信号的靶向治疗，旨在为 MA 治疗提供思路。
